Inhibitory effects of fluvastain and its metabolites on the formation of several reactive oxygen species

被引:44
作者
Nakashima, A
Ohtawa, M
Iwasaki, K
Wada, M
Kuroda, N
Nakashima, K
机构
[1] Novartis Pharma KK, Res Inst, Tsukuba, Ibaraki 3002611, Japan
[2] Nagasaki Univ, Sch Pharmaceut Sci, Nagasaki 8528521, Japan
[3] Nagasaki Univ, Grad Sch Pharmaceut Sci, Nagasaki 8528521, Japan
关键词
oxidative stress; antioxidant; HMG-CoA reductase inhibitor; fluvastatin; metabolite; reactive oxygen species;
D O I
10.1016/S0024-3205(01)01223-1
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 [基础医学];
摘要
We investigated the inhibitory effects of fluvastain (FV) and its metabolites (M-2, M-3, M-4, M-5, and M-7) on the formation of several reactive oxygen species (ROS), such as singlet oxygen (O-1(2)), superoxide anion (O-2(-)), hydroxy radical ((OH)-O-.), hypochlorite ion (OCL-, and linoleic acid peroxide (LOO.). Inhibitory effects of pravastatin (PV), simvastatin (SV), probucol (PR) and alpha -tocopherol (TOC) were also tested. The inhibitory effects of 5-hydroxy FV (M-2) and 6-hydroxy FV (M-3) on the formation of O-1(2), O-2(-), (OH)-O-., and OCL- were strongest. Scavenging of O-1(2) by M-4, M-5, (+)-FV, and (-)-FV was also noted. The inhibitory effects of (+)-FV on the formation Of O-1(2) were comparable to those of (-)-FV. PV, SV, PR and M-7 had little or no inhibitory effect on the formation of several ROS. In conclusion, FV and its metabolites, particulary M-2 and M-3, have the potential to protect against oxidative stress mediated by several ROS. (C) 2001 Elsevier Science Inc. All rights reserved.
引用
收藏
页码:1381 / 1389
页数:9
相关论文
共 27 条
[1]
Interactions of platelets, macrophages, and lipoproteins in hypercholesterolemia: Antiatherogenic effects of HMG-CoA reductase inhibitor therapy [J].
Aviram, M ;
Hussein, O ;
Rosenblat, M ;
Schlezinger, S ;
Hayek, T ;
Keidar, S .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1998, 31 (01) :39-45
[2]
Inhibitory effect of fluvastatin at doses insufficient to lower serum lipids on the catheter-induced thickening of intima in rabbit femoral artery [J].
Bandoh, T ;
Mitani, H ;
Niihashi, M ;
Kusumi, Y ;
Ishikawa, J ;
Kimura, M ;
Totsuka, T ;
Sakurai, I ;
Hayashi, S .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1996, 315 (01) :37-42
[3]
Direct vascular effects of HMG-CoA reductase inhibitors [J].
Bellosta, S ;
Bernini, F ;
Ferri, N ;
Quarato, P ;
Canavesi, M ;
Arnaboldi, L ;
Fumagalli, R ;
Paoletti, R ;
Corsini, A .
ATHEROSCLEROSIS, 1998, 137 :S101-S109
[4]
RELATIONSHIP BETWEEN MEVALONATE PATHWAY AND ARTERIAL MYOCYTE PROLIFERATION - IN-VITRO STUDIES WITH INHIBITORS OF HMG-COA REDUCTASE [J].
CORSINI, A ;
MAZZOTTI, M ;
RAITERI, M ;
SOMA, MR ;
GABBIANI, G ;
FUMAGALLI, R ;
PAOLETTI, R .
ATHEROSCLEROSIS, 1993, 101 (01) :117-125
[5]
CYNCHI O, 1995, J BIOLUMINESCENCE CH, V10, P261
[6]
DAIN JG, 1993, DRUG METAB DISPOS, V21, P567
[7]
Fischer V, 1999, DRUG METAB DISPOS, V27, P410
[8]
Reduced susceptibility of low density lipoprotein (LDL) to lipid peroxidation after fluvastatin therapy is associated with the hypocholesterolemic effect of the drug and its binding to the LDL [J].
Hussein, O ;
Schlezinger, S ;
Rosenblat, M ;
Keidar, S ;
Aviram, M .
ATHEROSCLEROSIS, 1997, 128 (01) :11-18
[9]
KATHAWALA FG, 1991, MED RES REV, V11, P121
[10]
PROBUCOL PREVENTS THE PROGRESSION OF ATHEROSCLEROSIS IN WATANABE HERITABLE HYPERLIPIDEMIC RABBIT, AN ANIMAL-MODEL FOR FAMILIAL HYPERCHOLESTEROLEMIA [J].
KITA, T ;
NAGANO, Y ;
YOKODE, M ;
ISHII, K ;
KUME, N ;
OOSHIMA, A ;
YOSHIDA, H ;
KAWAI, C .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1987, 84 (16) :5928-5931